Sensorion SA Stock
€0.61
Your prediction
Sensorion SA Stock
Pros and Cons of Sensorion SA in the next few years
Pros
Cons
Performance of Sensorion SA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sensorion SA | -2.240% | -5.556% | -10.000% | 97.419% | 53.000% | -64.336% | - |
| Cerenis Therapeutics Holding S.A. | -0.340% | 0.345% | 3.743% | 3.191% | -5.519% | 18.776% | 352.039% |
| Genoway S.A. Inh. | -1.270% | -7.363% | 0.515% | 6.849% | -11.565% | 2.228% | 143.750% |
| Hybrigenics S.A. | - | 40.000% | 100.000% | -85.801% | -62.963% | -95.449% | -91.250% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial review of Sensorion SA's financial statements and accompanying data, one notices a company deeply embedded in the typical patterns of biotechnology and medical research sector, characterized by significant research and development costs and fluctuations in financial health over time. The financials exhibit a pattern that is not out of the ordinary for an entity within this innovative yet unpredictable industry, given the nature of long-term investments into R&D and the regulatory hurdles faced before commercialization can occur. Let's delve into a thorough examination of the strengths and weaknesses as presented by the financials.
High Research & Development Expenditure: Sensorion SA appears steadfast in its commitment to R&D, with the figures illustrating a heavy reinvestment into the development of their biotechnological offerings. This is potentially indicative of a robust pipeline of products that could lead to profitability in the future.
Solid Cash Reserves: Throughout the years, the company has maintained a commendable level of cash and cash equivalents, ensuring that they have a buffer to support ongoing operations and investments.
Comments
News
Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sensorion Announces New Positive Secondary Efficacy Endpoints Data From SENS-401 Phase 2a Clinical Trial For The Preservation Of Residual Hearing Loss
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sensorion Announces the Appointment of Laurene Danon as Chief Financial Officer
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within